论文部分内容阅读
目的 :探讨博宁对骨转移患者骨吸收标志的影响。方法 :临床确诊为骨转移患者24例 ,一次性接受博宁90mg静点 ,观察治疗前及治疗后7天骨吸收标志的变化。结果 :治疗前尿钙、尿吡啶酚和脱氧吡啶酚较正常值分别为25 %、71 %和100 %患者升高。治疗后第7天尿钙、尿吡啶酚和脱氧吡啶酚较治疗前均明显下降(P<0 001) ,三项指标较治疗前分别下降了59 %、62%和60 % ,血钙治疗后也有明显下降(P<0 001) ,而血磷治疗前后无明显变化。治疗前后尿脱氧吡啶酚与尿钙均无明显相关性(P>0 05) ,而与尿吡啶酚在治疗前后均有明显的相关性(P<0 01)。结论 :博宁可使骨转移患者骨吸收标志明显下降 ,提示尿吡啶酚和脱氧吡啶酚可能在制定最适双膦酸盐类药物给药方案及骨转移治疗疗效的监测方面发挥潜在作用
Objective: To investigate the effect of Bonin on bone resorption markers in patients with bone metastasis. Methods: Twenty-four patients with bone metastases were diagnosed clinically. One hundred and ninety-four point Boning points were taken. The changes of bone resorption markers before and 7 days after treatment were observed. Results: Before treatment, urinary calcium, urinary pyridinol and deoxypyridin were 25%, 71% and 100% higher than normal respectively. On the 7th day after treatment, urinary calcium, urinary pyridinol and deoxypyridinol decreased significantly (P <0.001) before treatment, and the three indexes decreased by 59%, 62% and 60% Also significantly decreased (P <0 001), while no significant changes before and after treatment of phosphorus. Before and after treatment, urinary deoxypyridinol and urinary calcium had no significant correlation (P> 0.05), but were significantly correlated with urinary pyridinol before and after treatment (P <0.01). CONCLUSIONS: Bonin may markedly decrease bone resorption markers in patients with bone metastases, suggesting that urinary and total deoxypyridinol may play potential roles in the development of optimal bisphosphonates regimens and in monitoring the efficacy of bone metastases